Table 6.
Treatment regimen and number of treatment courses administered in CVID+PGD group.
| Treatment regimen in CVID+PGD | Total | Treatment courses with remission | Treatment courses without remission |
|---|---|---|---|
| steroids | 15 | 10 (66.7%) | 5 (33.3%) |
| rituximab with azathioprine | 12 | 11 (91.7%) | 1 (8.3%) |
| rituximab | 6 | 6 (100%) | 0 (0%) |
| steroids with IgRT | 6 | 4 (66.7%) | 2 (33.3%) |
| IgRT | 5 | 4 (80%) | 1 (20%) |
| MMF | 3 | 3 (100%) | 0 (0%) |
| anti-mycobacterial therapy | 2 | 0 (0%) | 2 (100%) |
| IgRT with MMF | 2 | 2 (100%) | 0 (0%) |
| infliximab | 2 | 2 (100%) | 0 (0%) |
| steroids with rituximab with azathioprine | 2 | 2 (100%) | 0 (0%) |
| cyclophosphamide | 1 | 0 (0%) | 1 (100%) |
| IgRT with infliximab | 1 | 1 (100%) | 0 (0%) |
| IgRT with methotrexate with hydroxychloroquine | 1 | 1 (100%) | 0 (0%) |
| IgRT with rituximab | 1 | 1 (100%) | 0 (0%) |
| rituximab with MMF | 1 | 1 (100%) | 0 (0%) |
| steroids with azathioprine | 1 | 1 (100%) | 0 (0%) |
| steroids with cyclophosphamide | 1 | 1 (100%) | 0 (0%) |
| steroids with cyclosporine | 1 | 1 (100%) | 0 (0%) |
| steroids with IgRT with anti-mycobacterial therapy | 1 | 1 (100%) | |
| 64 | 51 | 13 |
IgRT, immunoglobulin replacement therapy; IFN, interferon; MMF, mycophenolate mofetil. Percentages are of total number of treatment courses per treatment regimen.